-

BenevolentAI Notice of Interim Results

LONDON--(BUSINESS WIRE)--Regulatory News:

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, will announce its interim results for the six months ended 30 June 2023, on Thursday 21 September 2023.

Management will host an in-person briefing for analysts at 09:00am BST in London and, virtually via a webcast. A recording of the presentation will be made available on the Company´s website shortly afterward.

For more details, please contact FTI Consulting at BenevolentAI@fticonsulting.com or +44 (0) 20 3727 1000.

About BenevolentAI

BenevolentAI (AMS: BAI) is a leading developer of advanced artificial intelligence technologies that unlock the value of multimodal data, surface novel insights, and accelerate biomedical discovery. Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, the Company is developing an in-house drug pipeline of high-value assets. The Company is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Category: Non-regulatory

Contacts

Enquiries:

Investors:
Fleur Wood – VP Investor Relations
fleur.wood@benevolent.ai
investors@benevolent.ai
T: +44(0) 203 781 9360

Media:
Rajin Kang - VP Communications
rajin.kang@benevolent.ai
T: +44(0) 203 781 9360

FTI Consulting:
Ben Atwell/Simon Conway/Victoria Foster Mitchell
T: +44 203 727 1000
BenevolentAI@fticonsulting.com

Industry:

BenevolentAI

AEX:BAI
Release Summary
BenevolentAI will announce its interim results for the six months ended 30 June 2023, on Thursday 21 September 2023.
Release Versions
English

Contacts

Enquiries:

Investors:
Fleur Wood – VP Investor Relations
fleur.wood@benevolent.ai
investors@benevolent.ai
T: +44(0) 203 781 9360

Media:
Rajin Kang - VP Communications
rajin.kang@benevolent.ai
T: +44(0) 203 781 9360

FTI Consulting:
Ben Atwell/Simon Conway/Victoria Foster Mitchell
T: +44 203 727 1000
BenevolentAI@fticonsulting.com

More News From BenevolentAI

BenevolentAI: Appointment of Adviser

LONDON--(BUSINESS WIRE)--BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company’s Financial and Capital Markets Adviser, with immediate effect. Kenneth Mulvany, Deputy Chair of BenevolentAI, commented: “We are pleased to appoint Deutsche Numis as our UK and pan-European corporate broker. We look forward to working with their team to maximise our...

BenevolentAI: Leadership Team Change

LONDON--(BUSINESS WIRE)--Regulatory News: BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today announces a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support...

BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio

LONDON--(BUSINESS WIRE)--BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of target identificat...
Back to Newsroom